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Eur J Vasc Endovasc Surg (2015) 50, 3e4EDITORIALSo Many False DawnsUp to one-third of patients with critical limb ischaemia (CLI)
will have exhausted conventional treatment strategies
within 6 months of presentation and require a major
amputation.1 This has led to increasing interest in alterna-
tive therapeutic options for limb salvage, including “angio-
genic therapies” aimed at stimulating new blood vessel
growth.
Animal models of limb ischaemia were used to develop
the earliest angiogenic therapies and “spectacular” results
were achieved using angiogenic factors, including vascular
endothelial growth factor and ﬁbroblast growth factor.2 This
became the catalyst to move from “the bench” to “the
bedside”, and publications involving carefully selected pa-
tients soon followed. These included Isner et al.’s 1996
landmark study, which hinted at a clinically effective treat-
ment for “no option” CLI patients.3
However, several well-designed randomized trials
(including Regional Angiogenesis with VEGF in peripheral
arterial disease [RAVE] and TAMARIS) subsequently failed to
demonstrate clinical efﬁcacy.4,5 This was, perhaps, not un-
surprising as animal models poorly mimic the human con-
dition, and revascularization is a tightly orchestrated
process reliant upon a complex interplay involving multiple
angiogenic factors and a variety of cells, including endo-
thelial cells, pericytes, smooth muscle cells, and monocytes/
macrophages.6 These initially disappointing results then led
to a shift in focus towards cell-based therapies, in the hope
that populations of cells (e.g., mononuclear cells and
mesenchymal stem cells) might not only achieve sustained
production of the right “mix” of growth factors, but also
supply the constituent cells needed to form new vessels.7
Numerous clinical studies involving angiogenic cell ther-
apy, mostly driven by enthusiastic, rather than sensible,
design, have followed with (at best) only modest results. So
is angiogenic cell therapy a failed experiment or is there
hope of ultimately achieving clinical efﬁcacy? It would be
folly to think that a miracle cure is around the corner but
the lessons learnt and the positive trends observed do
justify ongoing efforts to develop a clinically useful treat-
ment strategy.
CELL TYPE
Most studies, to date, have used crude, ill-deﬁned, autol-
ogous cells with little understanding of their activity or fate
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ments have angiogenic properties. More effort should
therefore be made to select speciﬁc, potent angiogenic cell
types and deliver these to the limb in large numbers.
Monocyte/macrophage lineage cells, for example, have a
pivotal role in promoting a collateral circulation following
arterial occlusion by secreting proangiogenic factors and
contributing to the formation of a vascular plexus by
bridging sprouting endothelial cells.8 Monocytes not only
support angiogenesis, but are also powerful regulators of
collateral arteriogenesis.9 The latter is most likely to achieve
clinically effective revascularization because the vessels
formed by angiogenesis are transient, typically 8e12 mm in
diameter and lack a tunica media, whereas vessels formed
by arteriogenesis are up to 100 mm in size, possess a tunica
media, and are more likely to support adequate blood ﬂow.
Not all monocytes are alike, however, and it is now gener-
ally accepted that monocytes are a heterogenous popula-
tion of myeloid cells consisting of subsets that are either
inﬂammatory or angiogenic. Concentrates of angiogenic, as
opposed to inﬂammatory, monocytes promote limb salvage
in animal models and may be equally effective if used
appropriately in patients.10
RETENTION AND FATE OF DELIVERED CELLS
Limited studies involving cardiac cell therapy suggest that
the majority of cells either die or are washed out of the
myocardium shortly after delivery.11 The fate of cells
following injection into the limbs of patients with CLI has
not been investigated, but precipitous cell loss could ac-
count for the absence of efﬁcacy, prompting the pursuit of
strategies that might improve cell retention or survival. One
strategy involves encapsulation of cells within a polymeric
matrix, such as alginate, prior to delivery in an attempt to
prevent “wash out” of cells from host tissue.12 Encapsula-
tion facilitates bidirectional diffusion of nutrients, oxygen
and waste, and the secretion of therapeutic products, while
preventing host immune cells and antibodies from entering
the capsule. Creating this immune-privileged environment
allows allogeneic cell transplantation from young, healthy
subjects, circumventing the use of autologous cells har-
vested from aged patients with CLI with multiple comor-
bidities who are functionally impaired and prone to early
death.13
TRIAL DESIGN AND OUTCOME MEASURES
There remains a paucity of adequately powered, random-
ized, blinded, placebo-controlled trials of cell therapies, and
those few well-designed observational studies and meta-
4 Editorialanalyses fail to show beneﬁt.14 Attempts at instigating
robust trials have been blighted by cost, prohibitive regu-
latory processes, and a difﬁculty in recruiting patients. The
Phase III REVIVE trial (run by Aastrom Biosciences [now the
Vericel Corporation]) aimed to investigate “Ixmyelocel T”, a
proprietary cocktail of cells including monocyte/macro-
phages, lymphocytes, granulocytes, and stromal cells. This
was started in 2012 after encouraging Phase II (RESTORE-
CLI) results. However, REVIVE was terminated after 13
months with only 40 of the 594 target patients having been
enrolled despite having 70 recruitment sites. The company
decided to focus (instead) on trials of Ixmyelocel T in pa-
tients with dilated cardiomyopathy, for which it received an
orphan drug designation. The company cited (as reasons for
this strategic change) the need for smaller studies with
lower costs and faster regulatory approval.
It may also be overly ambitious to expect cell therapy to
retrieve the dramatic lack of vascular function in the harsh
biological environment found in critically ischaemic limbs of
“no option” patients. Perhaps patients might be treated at
an earlier stage, where cell therapy is chosen as an adjunct
to conventional interventions, especially where angioplasty/
stenting or bypass surgery is unlikely to succeed. Treatment
of short distance claudicants, with the aim of relieving
symptoms and preventing progression to CLI, may also be
more rewarding.
Trials should aspire to assessing limb salvage as the pri-
mary end point and avoid composite end points that are
more likely to demonstrate “efﬁcacy” but that are less
meaningful. For early-phase trials, however, more subtle
criteria such as improvements in limb perfusion could
demonstrate efﬁcacy involving fewer patients. Objective
modalities to measure limb perfusion are required, but
most still use measurement of ankle-brachial pressure index
and transcutaneous oxygen pressure, both of which are
inadequate surrogates of perfusion.15
The relentless global drive for regenerative medicine has
rapidly increased understanding of cell-based treatments
and has led to encouraging results in Phase I/II trials in CLI.
Clinicians will, however, remain unconvinced that these
therapies are a viable alternative to conventional treat-
ments until unequivocal efﬁcacy is demonstrated by well-
designed trials that elucidate a clear mechanism of action
for the therapeutic cells. This requires a concerted effort by
consortia of vascular specialists, basic scientists, bio-
engineers, and industrial partners working in parallel to
reﬁne treatments by interchanging research between the
bench and bedside.
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